Erythema multiforme due to Rofecoxib

Erythema Multiforme Etiopathogenesis and Treatment A Review Article

“…[4] Alongwith this various vaccines( hepatitis B, [6] smallpox, [7] diphtheria-tetanus), [8] viruses (cytomegalovirus, [9,10] hepatitis C, [11] human immunodeficiency virus and varicella zoster virus) and newer medicines (bupropion [Wellbutrin], [12][13][14] candesartan cilexetil [Atacand], [15] adalimumab [Humira], [16] ciprofloxacin [Cipro], [17] rofecoxib [Vioxx; withdrawn from the United States market] and metformin [Glucophage] have been implicated in the pathogenesis of erythema multiforme. [18,19] The HSV infection may remain clinically silent where recurrent erythema multiforme is secondary to HSV-1 and HSV-2 reactivation. [20] A study was conducted on 63 patients suffering from erythema multiforme where HSV-DNA was detected by Section: Dentistry polymerase chain reaction in skin biopsy specimens in 60 percent of patients with clinically diagnosed recurrent herpes associated erythema multiforme and in 50 percent of patients suffering from recurrent idiopathic erythema multiforme which has been defined as erythema multiforme with no apparent clinical history of HSV infection or drug ingestion.…”

Multifocal fixed drug eruption with COX-2 inhibitor-celecoxib

“…[12] However, reports of their safety, both cutaneous and systemic, are rather conflicting. [3–5] Most of the known adverse cutaneous reactions to COX-2 inhibitors have been attributed to either celecoxib or rofecoxib. They include urticaria/angioedema (by far the most common), Sweet's syndrome, vasculitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN), and maculopapular rash.…”